Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2010
11/03/2010CN101234149B Composition for treating pain of head, face and limbs and various tendons clonic convulsion and preparation thereof
11/03/2010CN101143181B Traditional Chinese medicinal composition for treating senile dementia and preparation method and application thereof
11/03/2010CN101029336B Reagent kit for predicting serotonin re-uptake inhibitor medicine effect
11/02/2010US7825255 Adenosine receptor selective modulators
11/02/2010US7825219 Binding protein; therapy for bone tumors
11/02/2010US7825158 treating amphetamine or methamphetamine dependence by administering an effective amount of (-)1-(benzofuran-2-yl)-2-propylaminopentane, or a pharmaceutical acceptable acid salt thereof, to an amphetamine or methamphetamine-dependent patient
11/02/2010US7825146 Sulfonamide derivative having isoxazole ring
11/02/2010US7825140 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
11/02/2010US7825130 Phosphatase and Tensin homolog deleted on chromosome Ten (PTEN), a tumor suppressor gene or calcium sensitive potassium channel modulators, comprising tetrazolylalkoxy-dihydrocarbostyril compounds such as Cilostazol , used for the treatment of Alzheimer's disease
11/02/2010US7825129 Thieno[2,3-c] isoquinolines for use as inhibitors of PARP
11/02/2010US7825113 2-oxy-benzoxazinone derivatives for the treatment of obesity
11/02/2010US7825105 such as 3,10-Dibenzyloxyminocycline, used to treat bacterial infections and neoplasms, as well as blocking tetracycline efflux and modulation of gene expression
11/02/2010US7824860 Application of aprataxin gene to diagnosis and treatment for early-onset spinocerebellar ataxia (EAOH)
11/02/2010US7824707 Backing and reservoir layers with drug; adhered over a prolonged period continuously to surface of skin; time-release agents; drug delivery
11/02/2010US7824683 Methods for augmenting an immune response using anti-CD40 antibodies
11/02/2010US7824670 Use of il6r/il6 chimera in nerve cell regeneration
11/02/2010CA2497544C Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
11/02/2010CA2470391C N,n'-disubstituted piperazine compounds and their use as analgesics
11/02/2010CA2460121C 3-substituted-4-pyrimidone derivatives
11/02/2010CA2457720C Medicine containing pyrimidine derivative
11/02/2010CA2457097C Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
11/02/2010CA2451798C Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
11/02/2010CA2446639C Composition for the prevention of addiction in pain management
11/02/2010CA2439784C Pyrazolopyrimidinone derivatives having pde7 inhibiting action
11/02/2010CA2437715C Carboline derivatives
11/02/2010CA2436361C Angiotensin ii antagonistic compound for use as analgesic and antiinflammatory agent
11/02/2010CA2417432C Modified polypeptides stabilized in a desired conformation and methods for producing same
11/02/2010CA2393523C Combination of cyamemazine and an atypical neuroleptic
11/02/2010CA2389491C Spiro(2h-1-benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors
10/2010
10/28/2010WO2010124122A1 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124121A1 Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
10/28/2010WO2010124119A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124116A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124114A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124112A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124108A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124102A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124086A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124082A1 Azetidinyl diamides as monoacylglycerol lipase inhibitors
10/28/2010WO2010124047A1 Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
10/28/2010WO2010123999A2 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
10/28/2010WO2010123956A2 2,5-disubstituted arylsulfonamide ccr3 antagonists
10/28/2010WO2010123838A2 Novel amide and amidine derivatives and uses thereof
10/28/2010WO2010123443A1 Pharmaceutical composition comprising 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n- propylcinnoline-3-carboxamide hydrogen sulphate.
10/28/2010WO2010123441A1 Crystalline form of 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3- carboxamide hydrogen sulphate, for treatment of anxiety disorders
10/28/2010WO2010123440A1 Pharmaceutical composition comprising 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n- propylcinnoline-3-carboxamide hydrogen sulphate and rate-controlling polymer
10/28/2010WO2010123103A1 Adhesive patch-containing package bag and method for storing adhesive patch
10/28/2010WO2010123006A1 Pyrrolidine compound
10/28/2010WO2010122980A1 Novel thyroid hormone β receptor agonist
10/28/2010WO2010122961A1 Method for preparing cell pharmaceutical
10/28/2010WO2010122927A1 Pharmaceutical agent for prevention or treatment of retarded nerve regeneration induced by diabetes
10/28/2010WO2010122151A1 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
10/28/2010WO2010122134A1 Nr2b-selective nmda-receptor antagonists
10/28/2010WO2010122064A1 Substituted naphthyridine derivatives and their medical use
10/28/2010WO2010121969A1 Method of treating or preventing a convulsive disorder in a patient in need thereof
10/28/2010WO2010121963A1 Resorcinol derivatives as hsp90 inhibitors
10/28/2010WO2010121834A2 Irak kinase family as novel target and biomarker for alzheimer
10/28/2010WO2010121621A1 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
10/28/2010WO2010121361A1 Tissue kallikrein for the treatment of huntington's disease
10/28/2010WO2010121358A1 Tissue kallikrein for the treatment of schizophrenia and bipolar disorder
10/28/2010WO2010110646A8 Aurones as selective pde inhibitors and their use in neurological conditions and disorders
10/28/2010WO2010100651A3 Compositions of polymeric myrcene
10/28/2010WO2010100477A3 Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
10/28/2010WO2010091981A3 Products comprising n-phenylpropenoyl amino acid amides and uses thereof
10/28/2010WO2010080977A3 Oral sustained release antidepressant formulation
10/28/2010WO2010074480A3 Novel pyrazolodiazepine compounds as a transglutaminase inhibitor, the preparation method thereof and a composition containing the same
10/28/2010WO2010068750A3 Compositons and method for treatment of mood and cognitive impairments
10/28/2010WO2009142732A3 Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
10/28/2010WO2009141321A3 Tablettable chewing gums comprising nicotine and a buffering agent
10/28/2010US20100273895 Formulations of cannabidiol and prodrugs of cannabidiol and methods of using the same
10/28/2010US20100273892 Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
10/28/2010US20100273891 Isoflavone metabolites
10/28/2010US20100273886 Formulations and methods for lyophilization and lyophilates provided thereby
10/28/2010US20100273878 Preventive or therapeutic drug for alzheimer-type dementia
10/28/2010US20100273865 Polypeptides involved in neuronal regeneration-associated gene expression
10/28/2010US20100273862 Phosphatases which activate map kinase pathways
10/28/2010US20100273857 Suppression of scn9a gene expression and/or function for the treatment of pain
10/28/2010US20100273854 Compositions and methods for inhibiting nadph oxidase expression
10/28/2010US20100273853 Novel isoindol derivatives as ep4 receptor agonists
10/28/2010US20100273852 Pharmaceutical composition
10/28/2010US20100273849 Metalloproteinase Inhibitors
10/28/2010US20100273847 Desferrioxamine conjugates, derivatives and analogues
10/28/2010US20100273844 Pharmaceutical compositions for treating or preventing migaines
10/28/2010US20100273835 Novel compounds
10/28/2010US20100273831 Fluoro alkyl substituted benzimidazole cannabinoid agonists
10/28/2010US20100273828 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
10/28/2010US20100273816 Quinazoline Compounds
10/28/2010US20100273814 ((phenyl)imidazolyl)methylheteroaryl compounds
10/28/2010US20100273813 Novel n-phenylacetamide inhibitors of the enzyme soat-1 and pharmaceutical/cosmetic compositions comprised thereof
10/28/2010US20100273810 Method of treating cognitive impairments and schizophrenias
10/28/2010US20100273805 Sulphide bridged derivatives as modulators of mglur5 733
10/28/2010US20100273802 New purine derivatives having, in particular, anti-proliferative properties, and their biological uses
10/28/2010US20100273797 Alpha-ketoamides and derivatives thereof
10/28/2010US20100273794 Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity
10/28/2010US20100273787 Kynurenine-aminotransferase inhibitors
10/28/2010US20100273785 2,5-disubstituted arylsulfonamide ccr3 antagonists
10/28/2010US20100273784 Fused ring heterocycles as potassium channel modulators
10/28/2010US20100273779 Pyridazinone Derivatives
10/28/2010US20100273776 Inhibition of alpha-synuclein toxicity
10/28/2010US20100273772 Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
1 ... 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 ... 1833